10 years of revenue, profit, cash flow and balance-sheet history through FY2025,
from SEC filings — with a computed, factual read of the trend.
Updated Overview →
Growth & profitability
Revenue has grown 51.2% per year over the past 5 years.
Operating margin has expanded, at 5.6% in the latest year.
Financial health
Total debt has grown slower than revenue (0.0% vs 51.2% per year).
Operating income covered interest expense 372× in the latest year.
Revenue & net income
RevenueNet income
Margins (gross / operating / net)
GrossOperatingNet
Return on equity & assets (ROE / ROA)
ROEROA
Free cash flow (CFO − capex)
Free cash flow
Cash vs total debt
CashTotal debt
Cash flow: operating / investing / financing
OperatingInvestingFinancing
Key annual figures
FY
Revenue
Net income
Gross M
Op M
ROE
ROA
FCF
Total debt
Cash
2025
$912M
$145M
85.4%
5.6%
18.6%
16.0%
$78M
—
$105M
2024
$803M
$54M
84.7%
4.5%
7.8%
6.6%
$91M
—
$150M
2023
$625M
-$21M
84.5%
-6.4%
-3.7%
-3.1%
$1M
—
$186M
2022
$408M
-$45M
83.8%
-11.7%
-9.0%
-7.9%
$2M
—
$442M
2021
$233M
-$42M
85.7%
-17.1%
-18.4%
-14.2%
-$25M
$25M
$214M
2020
$115M
-$57M
84.7%
-48.7%
-24.9%
-20.3%
-$56M
$25M
$191M
2019
$82M
-$33M
83.4%
-42.5%
-23.8%
-18.3%
-$36M
$25M
$23M
2018
$51M
-$22M
80.1%
-40.3%
-13.3%
-10.9%
-$19M
$25M
$97M
2017
—
-$18M
—
—
-1319.6%
-69.8%
-$16M
—
$9M
2016
—
-$19M
—
—
280.4%
—
-$18M
—
$7M
Revenue & net income
RevenueNet income
Margins (gross / operating / net)
GrossOperatingNet
Return on equity & assets (ROE / ROA)
ROEROA
Free cash flow (CFO − capex, quarterly)
Free cash flow
Cash vs total debt
CashTotal debt
Cash flow: operating / investing / financing
OperatingInvestingFinancing
Key quarterly figures
Quarter
Revenue
Net income
Gross M
Op M
ROE
ROA
FCF
Total debt
Cash
Sep '26
$207M
-$24M
86.0%
-13.9%
-2.9%
-2.6%
$39M
—
$191M
Jun '26
$201M
$314000
85.5%
-0.3%
0.0%
0.0%
$14M
—
$128M
Mar '26
$205M
-$11M
86.5%
-0.5%
-1.4%
-1.2%
$3M
—
$99M
Dec '25
$269M
$136M
86.6%
17.1%
17.4%
15.0%
$42M
—
$105M
Sep '25
$225M
$10M
85.8%
4.3%
1.5%
1.2%
$58M
—
$113M
Jun '25
$217M
-$4M
84.0%
-1.5%
-0.5%
-0.4%
-$6M
—
$107M
Mar '25
$201M
$3M
84.7%
-0.7%
0.5%
0.4%
-$15M
—
$54M
Dec '24
$240M
$35M
85.0%
13.3%
5.1%
4.4%
$62M
—
$150M
Sep '24
$203M
$18M
84.1%
7.0%
2.7%
2.3%
$44M
—
$148M
Jun '24
$196M
$10M
84.8%
2.6%
1.5%
1.3%
-$12M
—
$188M
Mar '24
$164M
-$10M
84.9%
-9.3%
-1.7%
-1.5%
-$3M
—
$175M
Dec '23
$193M
$15M
85.4%
4.8%
2.6%
2.2%
$9M
—
$186M
Sep '23
$153M
-$9M
84.1%
-8.8%
-1.6%
-1.3%
-$3M
—
$330M
Jun '23
$151M
-$12M
83.9%
-11.0%
-2.3%
-1.9%
$237000
—
$467M
Mar '23
$128M
-$15M
84.4%
-15.2%
-3.1%
-2.7%
-$5M
—
$442M
Dec '22
$138M
—
83.9%
-0.2%
0.0%
0.0%
$16M
—
$442M
Sep '22
$109M
-$17M
81.9%
-15.7%
-3.6%
-3.2%
$7M
—
$418M
Jun '22
$91M
-$14M
84.5%
-15.3%
-6.4%
-5.0%
-$7M
$21M
$187M
Mar '22
$69M
-$17M
85.6%
-23.1%
-7.4%
-5.8%
-$14M
$25M
$203M
Dec '21
$78M
—
85.8%
-2.3%
0.0%
0.0%
$201000
$25M
$214M
Valuation over time
How the market has priced INSP against its own fundamentals since 2023-03 —
each month-end's share price set against the most recent annual filing, so the multiple moves
as price runs ahead of (or behind) earnings. Split-adjusted.
The price-to-earnings ratio has fallen from 100.5× (Dec '24) to 13.5× (Nov '26).
The price-to-sales ratio has fallen from 16.6× (Mar '23) to 2.1× (Nov '26).
Price / earnings (P/E)
P/E
Price / sales (P/S)
P/S
Frequently asked questions
Is INSP growing its revenue and profit?
Over the past 5 years, Inspire Medical Systems, Inc.'s revenue has grown 51.2% per year. These are computed facts, not advice.
How much debt does INSP have?
As of FY2025, Inspire Medical Systems, Inc. reported — of total debt against $105M of cash; operating income covered interest expense 372×.
What is INSP's profit margin?
In FY2025, gross margin was 85.4%, operating margin 5.6%, and net margin 15.9%.
What is INSP's P/E ratio?
Inspire Medical Systems, Inc.'s P/E (TTM) is 19.42 as of the 2026-11-02 close — market cap ÷ net income over the trailing twelve months where four consecutive quarters are reported, otherwise the latest fiscal year, the same figure as on the INSP stock page. The valuation chart above sets each month-end's price against the latest annual net income instead, so its latest point (about 13.5× as of Nov '26) can differ. These are computed facts, not advice.
Where does this data come from?
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), split-adjusted; price return — dividends not reinvested ·
growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price
against the latest annual filing. Informational only — not investment advice.